Principal Investigator

Balazs
Halmos
Awardee Organization

Montefiore Medical Center (Bronx, Ny)
United States

Fiscal Year
2022
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

MINORITY-BASED COMMUNITY ONCOLOGY PROGRAM

The overall goals of the Montefiore-Einstein minority-based NCORP community site are to advance the diagnosis, prevention, and management of early and advanced cancer by participating in NCORP trials as a minority/underserved community site, and contributing scientifically and administratively to the NCORP research bases. This will be accomplished by leveraging the strengths of the Montefiore Health System (MHS), including Montefiore Medical Center (MMC), which brings strengths in integrated patient care and innovative health care delivery systems in an academic medical center serving a largely minority population, and the Albert Einstein College of Medicine and Cancer Center (Einstein), which brings strength in training and education, and in baslc, translational, and clinical research through its NCIdesignated cancer center. The MMC-Einstein program also brings critical leadership to the NCORP Research Bases, including ECOG-ACRIN, Alliance, and NRG, including leadership roles at the level of the group chair's office, scientific committee chair (or co-chair), and protocol chair (or co-chair). Our plans build upon our long-standing involvement in all aspects of cancer research as a main member of ECOG for 45 years and an NCI-designated cancer center for 48 years, and a strong history of minority accrual to cancer treatment trials (about 65%of all patients). MMC serves the Bronx, an urban community of 1.47 million residents, of whom 89% are minorities and 29% live below the federal poverty level. In the prior funding period we had a strong track record scientific contributions to the NCORP research bases, and met our accrual targets with exceptionally strong minority participation. In the next funding period, we will continue our strong leadership in cancer therapeutics (EA2165), expand the spectrum of our activities to include new programs in cancer imaging and screening (TMIST), cancer control/prevention (EAZ171), and cancer care delivery research (CCDR). The MMC-Einstein NCORP program is led by faculty with experience in cancer therapeutics and biomarker research (J. Sparano, MD), precision medicine and immunoncology (B. Halmos, MD), and CCDR and cancer prevention/control (B. Rapkin, PhD), and is supported by a cadre of other investigators with a broad range of expertise, some of whom benefited from NCIfunded K12 training program in clinical cancer research.

Publications

  • Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16. Epub 2016 Mar 9. PMID: 26969090
  • Trosman JR, Carlos RC, Simon MA, Madden DL, Gradishar WJ, Benson AB 3rd, Rapkin BD, Weiss ES, Gareen IF, Wagner LI, Khan SA, Bunce MM, Small A, Weldon CB. Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. Journal of oncology practice. 2016 Nov;12(11):1101-1113. Epub 2016 Oct 31. PMID: 27577619
  • Connolly RM, Zhao F, Miller KD, Lee MJ, Piekarz RL, Smith KL, Brown-Glaberman UA, Winn JS, Faller BA, Onitilo AA, Burkard ME, Budd GT, Levine EG, Royce ME, Kaufman PA, Thomas A, Trepel JB, Wolff AC, Sparano JA. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Oct 1;39(28):3171-3181. Epub 2021 Aug 6. PMID: 34357781
  • Schneider BP, Shen F, Jiang G, O'Neill A, Radovich M, Li L, Gardner L, Lai D, Foroud T, Sparano JA, Sledge GW Jr, Miller KD. Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO precision oncology. 2017;2017. Epub 2017 Aug 21. PMID: 29333527
  • Lehman CD, Gatsonis C, Romanoff J, Khan SA, Carlos R, Solin LJ, Badve S, McCaskill-Stevens W, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Gareen I, Snyder BS, Wagner LI, Miller KD, Sparano JA, Comstock C. Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. JAMA oncology. 2019 Jul 1;5(7):1036-1042. PMID: 30653209
  • Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Vance GH, Wiernik P, Wiktor AE, Zhang Y, Tallman MS, ECOG-ACRIN Cancer Research Group. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leukemia research. 2017 Aug;59:55-64. Epub 2017 May 12. PMID: 28551161
  • Gomari DP, Schweickart A, Cerchietti L, Paietta E, Fernandez H, Al-Amin H, Suhre K, Krumsiek J. Variational autoencoders learn transferrable representations of metabolomics data. Communications biology. 2022 Jun 30;5(1):645. PMID: 35773471
  • Montefiori LE, Bendig S, Gu Z, Chen X, Pölönen P, Ma X, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu B, Cheng Z, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu C, Valentine MB, Rashkovan M, Luger S, Litzow MR, Rowe JM, den Boer ML, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang W, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang J, Kern W, Haferlach T, Wu G, Dick JE, Klco JM, Haferlach C, Mullighan CG. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer discovery. 2021 Nov;11(11):2846-2867. Epub 2021 Jun 8. PMID: 34103329
  • Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Reply to K. Ando et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Jun 10;39(17):1947-1948. Epub 2021 Apr 1. PMID: 33793318
  • Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, Verma A, Goel S, Halmos B. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nature cancer. 2021 Apr;2(4):392-399. Epub 2021 Mar 22. PMID: 34661163
  • Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature genetics. 2019 Feb;51(2):296-307. Epub 2019 Jan 14. PMID: 30643249
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine. 2018 Jul 12;379(2):111-121. Epub 2018 Jun 3. PMID: 29860917
  • Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, Tevaarwerk AJ, Carlos RC, Albain KS, Olson JA Jr, Goetz MP, Pritchard KI, Hayes DF, Geyer CE, Dees EC, McCaskill-Stevens WJ, Minasian LM, Sledge GW Jr, Cella D. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jun 10;38(17):1875-1886. Epub 2020 Apr 9. PMID: 32271671
  • Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. Journal of the National Cancer Institute. 2021 Nov 29;113(12):1744-1750. PMID: 34010423
  • Shapiro LC, Thakkar A, Gali R, Gonzalez-Lugo JD, Bazarbachi AH, Rahman S, Pradhan K, Fehn K, Abreu M, Kornblum N, Gritsman K, Goldfinger M, Shastri A, Mantzaris I, Braunschweig I, Halmos B, Verma A, McCort M, Bachier-Rodriguez L, Sica RA. High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination. Leukemia & lymphoma. 2022 Oct;63(10):2484-2488. Epub 2022 May 20. PMID: 35593019
  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine. 2015 Nov 19;373(21):2005-14. Epub 2015 Sep 27. PMID: 26412349
  • Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast cancer research and treatment. 2017 Sep;165(2):375-382. Epub 2017 Jun 16. PMID: 28623430
  • Klugman M, Fazzari M, Xue X, Ginsberg M, Rohan TE, Halmos B, Hanna DB, Shuter J, Hosgood HD 3rd. The associations of CD4 count, CD4/CD8 ratio, and HIV viral load with survival from non-small cell lung cancer in persons living with HIV. AIDS care. 2022 Aug;34(8):1014-1021. Epub 2021 Jun 1. PMID: 34074183
  • Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. Journal for immunotherapy of cancer. 2019 Mar 12;7(1):70. PMID: 30871628
  • Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Nov 20;33(33):3938-44. Epub 2015 Sep 14. PMID: 26371148
  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. PMID: 34092112
  • Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022 Jul 14;140(2):112-120. PMID: 35427411
  • Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, Mulcahy MF, Armstrong KI, Nabbout NH, Kalnicki S, El-Rayes BF, Onitilo AA, Moriarty DJ, Fitzgerald TJ, Benson AB 3rd. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Mar;35(7):718-726. Epub 2017 Jan 9. PMID: 28068178
  • Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA oncology. 2020 Mar 1;6(3):367-374. PMID: 31566680
  • Bliton JN, Parides M, Muscarella P, Papalezova KT, In H. Understanding Racial Disparities in Gastrointestinal Cancer Outcomes: Lack of Surgery Contributes to Lower Survival in African American Patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2021 Mar;30(3):529-538. Epub 2020 Dec 10. PMID: 33303644
  • Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart T, Lu Y, Pan Q, Yu J, Hibshoosh H, Guo H, Andreopoulou E, Wiechmann L, Crew K, Sparano J, Hershman D, Connolly E, Saenger Y, Kalinsky K. Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Frontiers in oncology. 2020 Jun 16;10:968. doi: 10.3389/fonc.2020.00968. eCollection 2020. PMID: 32612958
  • Chou SS, Romanoff J, Lehman CD, Khan SA, Carlos R, Badve SS, Xiao J, Corsetti RL, Javid SH, Spell DW, Han LK, Sabol JL, Bumberry JR, Gareen IF, Snyder BS, Gatsonis C, Wagner LI, Wolff AC, Miller KD, Sparano JA, Comstock CE, Rahbar H. Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). Radiology. 2021 Oct;301(1):66-77. Epub 2021 Aug 3. PMID: 34342501
  • Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer discovery. 2020 Jul;10(7):935-941. Epub 2020 May 1. PMID: 32357994
  • Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb;35(4):394-401. Epub 2016 Nov 21. PMID: 27870571
  • Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, Foroud T, Sledge GW Jr. Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Jan 1;23(1):43-51. Epub 2016 Dec 19. PMID: 27993963
  • Kim G, Pastoriza JM, Condeelis JS, Sparano JA, Filippou PS, Karagiannis GS, Oktay MH. The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression. Frontiers in oncology. 2020 Jun 30;10:1022. doi: 10.3389/fonc.2020.01022. eCollection 2020. PMID: 32714862
  • Ko H, Baghdadi Y, Love C, Sparano JA. Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy. Journal of the National Comprehensive Cancer Network : JNCCN. 2020 Sep;18(9):1240-1246. PMID: 32886897
  • Obeng-Gyasi S, O'Neill A, Zhao F, Kircher SM, Lava TR, Wagner LI, Miller KD, Sparano JD, Sledge GW, Carlos RC. Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer. Cancer medicine. 2021 Jan;10(1):45-52. Epub 2020 Dec 2. PMID: 33264502
  • Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, O'Brien S, Barrientos JC, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba H, Stone R, Litzow MR, Tallman MS, Shanafelt TD, Kay NE. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021 Dec 30;138(26):2810-2827. PMID: 34407545
  • Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. Cancer chemotherapy and pharmacology. 2020 Apr;85(4):741-751. Epub 2020 Feb 13. PMID: 32055930
  • Baer C, Kimura S, Rana MS, Kleist AB, Flerlage T, Feith DJ, Chockley P, Walter W, Meggendorfer M, Olson TL, Cheon H, Olson KC, Ratan A, Mueller ML, Foran JM, Janke LJ, Qu C, Porter SN, Pruett-Miller SM, Kalathur RC, Haferlach C, Kern W, Paietta E, Thomas PG, Babu MM, Loughran TP Jr, Iacobucci I, Haferlach T, Mullighan CG. CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk. Nature genetics. 2022 May;54(5):637-648. Epub 2022 May 5. PMID: 35513723
  • Sparano JA, Brawley OW. Deconstructing Racial and Ethnic Disparities in Breast Cancer. JAMA oncology. 2021 Mar 1;7(3):355-356. PMID: 33475709
  • Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Annals of oncology : official journal of the European Society for Medical Oncology. 2021 Jun;32(6):787-800. Epub 2021 Mar 19. PMID: 33746047
  • In H, Langdon-Embry M, Gordon L, Schechter CB, Wylie-Rosett J, Castle PE, Margaret Kemeny M, Rapkin BD. Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study. The Journal of surgical research. 2018 Jul;227:246-256. Epub 2018 Apr 3. PMID: 29622399
  • Paietta E, Roberts KG, Wang V, Gu Z, Buck GAN, Pei D, Cheng C, Levine RL, Abdel-Wahab O, Cheng Z, Wu G, Qu C, Shi L, Pounds S, Willman CL, Harvey R, Racevskis J, Barinka J, Zhang Y, Dewald GW, Ketterling RP, Alejos D, Lazarus HM, Luger SM, Foroni L, Patel B, Fielding AK, Melnick A, Marks DI, Moorman AV, Wiernik PH, Rowe JM, Tallman MS, Goldstone AH, Mullighan CG, Litzow MR. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood. 2021 Sep 16;138(11):948-958. PMID: 33895809
  • Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakkar A, Shapiro LC, Kabarriti R, Ruiz RE, Andrews EM, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, Verma A. Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. Cancer cell. 2022 Apr 11;40(4):343-345. Epub 2022 Feb 22. PMID: 35219358
  • Sparano JA. Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer-Reply. JAMA oncology. 2020 Apr 1;6(4):586. PMID: 32053157
  • Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, Shah AP, Sklow C, Alfieri G, Racine A, Wolgast L, Greenberger L, Verma A, Halmos B. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer cell. 2022 Jan 10;40(1):3-5. Epub 2021 Nov 16. PMID: 34838186
  • Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher JP, Wilding G. Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). Clinical genitourinary cancer. 2015 Dec;13(6):531-539.e1. Epub 2015 Jul 17. PMID: 26272427
  • Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R, International Immuno-Oncology Biomarker Working Group, Hyytiäinen A, Hida AI, Thompson A, Lefevre A, Gown A, Lo A, Sapino A, Moreira AM, Richardson A, Vingiani A, Bellizzi AM, Guerrero A, Grigoriadis A, Garrido-Castro AC, Cimino-Mathews A, Srinivasan A, Acs B, Singh B, Calhoun B, Haibe-Kans B, Solomon B, Thapa B, Nelson BH, Ballesteroes-Merino C, Criscitiello C, Boeckx C, Colpaert C, Quinn C, Chennubhotla CS, Solinas C, Drubay D, Sabanathan D, Peeters D, Zardavas D, Höflmayer D, Johnson DB, Thompson EA, Perez E, ElGabry EA, Blackley EF, Reisenbichler E, Chmielik E, Gaire F, Lu FI, Azmoudeh-Ardalan F, Peale F, Hirsch FR, Acosta-Haab G, Farshid G, Broeckx G, Koeppen H, Haynes HR, McArthur H, Joensuu H, Olofsson H, Cree I, Nederlof I, Frahm I, Brcic I, Chan J, Ziai J, Brock J, Weseling J, Giltnane J, Lemonnier J, Zha J, Ribeiro J, Lennerz JK, Carter JM, Hartman J, Hainfellner J, Le Quesne J, Juco JW, van den Berg J, Sanchez J, Cucherousset J, Adam J, Balko JM, Saeger K, Siziopikou K, Sikorska K, Weber K, Steele KE, Emancipator K, El Bairi K, Allison KH, Korski K, Buisseret L, Shi L, Kooreman LFS, Molinero L, Estrada MV, Van Seijen M, Lacroix-Triki M, Sebastian MM, Balancin ML, Mathieu MC, van de Vijver M, Rebelatto MC, Piccart M, Goetz MP, Preusser M, Khojasteh M, Sanders ME, Regan MM, Barnes M, Christie M, Misialek M, Ignatiadis M, de Maaker M, Van Bockstal M, Harbeck N, Tung N, Laudus N, Sirtaine N, Burchardi N, Ternes N, Radosevic-Robin N, Gluz O, Grimm O, Nuciforo P, Jank P, Kirtani P, Watson PH, Jelinic P, Francis PA, Russell PA, Pierce RH, Hills R, Leon-Ferre R, de Wind R, Shui R, Leung S, Tabbarah S, Souza SC, O'Toole S, Swain S, Dudgeon S, Willis S, Ely S, Bedri S, Irshad S, Liu S, Hendry S, Bianchi S, Bragança S, Paik S, Luz S, Gevaert T, d'Alfons T, John T, Sugie T, Kurkure U, Bossuyt V, Manem V, Cámaea VP, Tong W, Tran WT, Wang Y, Allory Y, Husain Z, Bago-Horvath Z. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ breast cancer. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. eCollection 2020. PMID: 32411819
  • Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature reviews. Clinical oncology. 2021 May;18(5):320. PMID: 33758378
  • Makower D, Lin J, Xue X, Sparano JA. Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. NPJ breast cancer. 2021 Mar 1;7(1):20. PMID: 33649322
  • Ramos JC, Sparano JA, Chadburn A, Reid EG, Ambinder RF, Siegel ER, Moore PC, Rubinstein PG, Durand CM, Cesarman E, Aboulafia D, Baiocchi R, Ratner L, Kaplan L, Capoferri AA, Lee JY, Mitsuyasu R, Noy A. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020 Sep 10;136(11):1284-1297. PMID: 32430507
  • Kempin S, Sun Z, Kay NE, Paietta EM, Mazza JJ, Ketterling RP, Frankfurt O, Claxton DF, Saltzman JN, Srkalovic G, Callander NS, Gross G, Tallman MS. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903). Acta haematologica. 2019;142(4):224-232. Epub 2019 Jul 23. PMID: 31336367
  • Sparano JA, Gray R. TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Jul 20;37(21):1841-1842. Epub 2019 Jun 7. PMID: 31173552
  • Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Apr 10;36(11):1088-1095. Epub 2018 Mar 9. PMID: 29522362
  • Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, Sledge GW, Cella D, Wagner LI, Carlos RC. Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. Cancer. 2021 Jul 15;127(14):2545-2552. Epub 2021 Apr 1. PMID: 33793979
  • Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ breast cancer. 2018 Jan 11;4:1. doi: 10.1038/s41523-017-0053-3. eCollection 2018. PMID: 29354686
  • Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, Verma A, Halmos B. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer cell. 2021 Aug 9;39(8):1081-1090.e2. Epub 2021 Jun 5. PMID: 34133951
  • Garcia SF, Gray RJ, Sparano JA, Tevaarwerk AJ, Carlos RC, Yanez B, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. Cancer. 2022 Feb 1;128(3):536-546. Epub 2021 Oct 6. PMID: 34614209
  • Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. The New England journal of medicine. 2019 Jun 20;380(25):2395-2405. Epub 2019 Jun 3. PMID: 31157962
  • Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Sep 1;36(25):2621-2629. Epub 2018 Jul 24. PMID: 30040523
  • Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. Journal of the National Cancer Institute. 2021 Apr 6;113(4):390-399. PMID: 32986828
  • Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O'Neill A, Smith ML, Railey E, White C, Partridge A, Sparano J, Davidson NE, Foroud T, Sledge GW Jr. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Nov 15;21(22):5082-5091. Epub 2015 Jul 2. PMID: 26138065
  • Haddad TC, He J, O'Sullivan CC, Chen B, Northfelt D, Dueck AC, Ballman KV, Tenner KS, Linden H, Sparano JA, Hopkins JO, De Silva C, Perez EA, Haluska P, Goetz MP. Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). Breast cancer research and treatment. 2021 Jul;188(2):477-487. Epub 2021 Apr 14. PMID: 33852121
  • Rapkin BD, Weiss E, Lounsbury D, Michel T, Gordon A, Erb-Downward J, Sabino-Laughlin E, Carpenter A, Schwartz CE, Bulone L, Kemeny M. Reducing Disparities in Cancer Screening and Prevention through Community-Based Participatory Research Partnerships with Local Libraries: A Comprehensive Dynamic Trial. American journal of community psychology. 2017 Sep;60(1-2):145-159. Epub 2017 Sep 15. PMID: 28913882
  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Nov 1;39(31):3522-3524. Epub 2021 Sep 23. PMID: 34554848
  • Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH, ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology. 2017 Dec;18(12):1610-1623. Epub 2017 Nov 9. PMID: 29129443
  • Sparano JA, Henry NL. Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal? Journal of the National Cancer Institute. 2019 Apr 1;111(4):339-341. PMID: 30312420
  • Schneider BP, Lai D, Shen F, Jiang G, Radovich M, Li L, Gardner L, Miller KD, O'Neill A, Sparano JA, Xue G, Foroud T, Sledge GW Jr. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget. 2016 Dec 13;7(50):82244-82253. PMID: 27732968
  • Pisano ED, Gatsonis C, Sparano J, Troester MA, Yaffe M, Cole E, Schnall MD. RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. Journal of the National Cancer Institute. 2021 Jul 1;113(7):938-939. PMID: 33783531
  • Sparano J, O'Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, Sledge GW, Miller KD. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology. 2018 Dec 1;4(12):1700-1706. PMID: 30054636
  • Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature reviews. Clinical oncology. 2021 May;18(5):313-319. Epub 2021 Mar 15. PMID: 33723371
  • Oh SY, Rahman S, Sparano JA. Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. Expert opinion on pharmacotherapy. 2021 Jun;22(8):981-1003. Epub 2021 Jun 7. PMID: 33646064
  • Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. The oncologist. 2020 Aug;25(8):e1158-e1169. Epub 2020 Jun 17. PMID: 32452601
  • In H, Solsky I, Castle PE, Schechter CB, Parides M, Friedmann P, Wylie-Rosett J, Kemeny MM, Rapkin BD. Utilizing Cultural and Ethnic Variables in Screening Models to Identify Individuals at High Risk for Gastric Cancer: A Pilot Study. Cancer prevention research (Philadelphia, Pa.). 2020 Aug;13(8):687-698. Epub 2020 May 14. PMID: 32409594
  • Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, McCann JC, Winegarden JD, Kassem MA, Mohamed MK, Rothman JM, Lyss AP, Horn L, Stinchcombe TE, Schiller JH. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Sep 10;37(26):2360-2367. Epub 2019 Jul 30. PMID: 31361535
  • Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M Jr, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Dec 1;37(34):3266-3274. Epub 2019 Oct 16. PMID: 31618129
  • Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551-8. Epub 2016 Jan 11. PMID: 26755712
  • Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast cancer research and treatment. 2018 Jun;169(2):359-369. Epub 2018 Jan 31. PMID: 29388015
  • Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, Levine R, Leslie C, Lengner CJ, Kharas MG. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. The Journal of clinical investigation. 2015 Mar 2;125(3):1286-98. Epub 2015 Feb 9. PMID: 25664853
  • Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, Herranz D, Bansal M, Girardi T, Paietta E, Tallman MS, Rowe JM, De Keersmaecker K, Califano A, Ferrando AA. Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proceedings of the National Academy of Sciences of the United States of America. 2017 Feb 21;114(8):2006-2011. Epub 2017 Feb 7. PMID: 28174276
  • Kim G, Pastoriza JM, Qin J, Lin J, Karagiannis GS, Condeelis JS, Yothers G, Anderson S, Julian T, Entenberg D, Rohan TE, Xue X, Sparano JA, Oktay MH. Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials. Cancer. 2022 Jul 15;128(14):2728-2735. Epub 2022 May 17. PMID: 35578919
  • Rashkovan M, Albero R, Gianni F, Perez-Duran P, Miller HI, Mackey AL, Paietta EM, Tallman MS, Rowe JM, Litzow MR, Wiernik PH, Luger S, Sulis ML, Soni RK, Ferrando AA. Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. Cancer discovery. 2022 Mar 1;12(3):856-871. PMID: 34711640
  • Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jul 20;33(21):2353-60. Epub 2015 Jun 15. PMID: 26077235
  • Sparano JA. Prognostic gene expression assays in breast cancer: are two better than one? NPJ breast cancer. 2018 May 22;4:11. doi: 10.1038/s41523-018-0063-9. eCollection 2018. PMID: 29845110
  • Ganzel C, Sun Z, Baslan T, Zhang Y, Gönen M, Abdel-Wahab OI, Racevskis J, Garrett-Bakelman F, Lowe SW, Fernandez HF, Ketterling R, Luger SM, Litzow M, Lazarus HM, Rowe JM, Tallman MS, Levine RL, Paietta E. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leukemia research. 2022 Dec;123:106971. Epub 2022 Oct 21. PMID: 36332294
  • Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. Journal for immunotherapy of cancer. 2021 May;9. (5). PMID: 33963015
  • Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer cell. 2015 Jul 13;28(1):114-28. Epub 2015 Jun 11. PMID: 26073130
  • Xu W, Puligandla M, Manola J, Bullock AJ, Tamasauskas D, McDermott DF, Atkins MB, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Bhatt RS. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Oct 15;25(20):6098-6106. Epub 2019 Aug 30. PMID: 31471309
  • Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Coutré SE, Lancet J, Litzow MR, Luger SM, Young NS, Tallman MS. Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta haematologica. 2016;136(4):210-218. Epub 2016 Sep 16. PMID: 27632567
  • Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. Journal for immunotherapy of cancer. 2022 Jan;10. (1). PMID: 35074904
  • Ignatz-Hoover JJ, Wang V, Mackowski NM, Roe AJ, Ghansah IK, Ueda M, Lazarus HM, de Lima M, Paietta E, Fernandez H, Cripe L, Tallman M, Wald DN. Aberrant GSK3β nuclear localization promotes AML growth and drug resistance. Blood advances. 2018 Nov 13;2(21):2890-2903. PMID: 30385433
  • Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW, Sun Z, Tallman MS, Patel J, Gönen M, Abdel-Wahab O, Levine RL, Estey EH. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. 2015 Oct;29(10):2104-7. Epub 2015 Mar 16. PMID: 25772026
  • Ganzel C, Lee JW, Fernandez HF, Paietta EM, Luger SM, Lazarus HM, Cripe LD, Douer D, Wiernik PH, Rowe JM, Tallman MS, Litzow MR. CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. Blood advances. 2021 Nov 23;5(22):4560-4568. PMID: 34597373
  • Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuwille WMB, Nacson J, Hulse M, Keith K, Madzo J, Caruso LB, Gazze Z, Lian Z, Padella A, Chitrala KN, Bartholdy BA, Matlawska-Wasowska K, Di Marcantonio D, Simonetti G, Greiner G, Sykes SM, Valent P, Paietta EM, Tallman MS, Fernandez HF, Litzow MR, Minden MD, Huang J, Martinelli G, Vassiliou GS, Tempera I, Piwocka K, Johnson N, Challen GA, Skorski T. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer research. 2021 Oct 1;81(19):5089-5101. Epub 2021 Jul 2. PMID: 34215619
  • Kumar AJ, Gimotty PA, Gelfand JM, Buck G, Rowe JM, Goldstone AH, Fielding A, Marks DI, Litzow M, Paietta E, Lazarus HM, Tallman MS, Luger SM, Loren AW. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. American journal of hematology. 2016 Nov;91(11):1107-1112. Epub 2016 Aug 22. PMID: 27468137
  • Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA oncology. 2019 Nov 1;5(11):1582-1588. PMID: 31486832
  • Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Feb 20;39(6):557-564. Epub 2020 Dec 11. PMID: 33306425
  • Wang J, Bhakta N, Ayer Miller V, Revsine M, Litzow MR, Paietta E, Fedoriw Y, Roberts KG, Gu Z, Mullighan CG, Jones CD, Alexander TB. Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing. JCO precision oncology. 2022 Apr;6:e2100326. PMID: 35442720
  • Thakkar A, Pradhan K, Duva B, Carreno JM, Sahu S, Thiruthuvanathan V, Campbell S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, Verma A, Halmos B. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. eLife. 2023 Mar 28;12. PMID: 36975207
  • Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. American journal of hematology. 2018 Aug;93(8):1074-1081. PMID: 29905379
  • Ganzel C, Wang XV, Rowe JM, Richards SM, Buck G, Marks DI, Litzow MR, Paietta EM, Foroni L, Luger SM, Willman CL, Mullighan CG, Roberts KG, Wiernik PH, Douer D, Lazarus HM, Tallman MS, Goldstone AH. At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. British journal of haematology. 2020 Oct;191(1):37-43. Epub 2020 Mar 27. PMID: 32220069
  • Luger SM, Wang VX, Rowe JM, Litzow MR, Paietta E, Ketterling RP, Lazarus H, Rybka WB, Craig MD, Karp J, Cooper BW, Makary AZ, Kaminer LS, Appelbaum FR, Larson RA, Tallman MS. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leukemia research. 2021 Dec;111:106736. Epub 2021 Oct 28. PMID: 34773794
  • Sparano JA, O'Neill A, Graham N, Northfelt DW, Dang CT, Wolff AC, Sledge GW, Miller KD. Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. NPJ breast cancer. 2022 Feb 8;8(1):16. PMID: 35136076
  • Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature medicine. 2016 Dec;22(12):1488-1495. Epub 2016 Nov 14. PMID: 27841873
  • Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, Litzow MR, Lee JW, Luger SM, Lazarus HM, Cripe LD, Wiernik PH, Tallman MS. Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Oct 10;34(29):3544-3553. PMID: 27573652
  • Simon MA, Trosman JR, Rapkin B, Rittner SS, Adetoro E, Kirschner MC, O'Brian CA, Tom LS, Weldon CB. Systematic Patient Navigation Strategies to Scale Breast Cancer Disparity Reduction by Improved Cancer Prevention and Care Delivery Processes. JCO oncology practice. 2020 Dec;16(12):e1462-e1470. Epub 2020 Jun 23. PMID: 32574137
  • Rapaport F, Seier K, Neelamraju Y, Hassane D, Baslan T, Gildea DT, Haddox S, Lee T, Murdock HM, Sheridan C, Thurmond A, Wang L, Carroll M, Cripe LD, Fernandez H, Mason CE, Paietta E, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Gönen M, Levine R, Melnick AM, Kleppe M, Garrett-Bakelman FE. Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. Blood cancer journal. 2022 Sep 23;12(9):137. PMID: 36151075
  • Wendorff AA, Quinn SA, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, Litzow MR, Tallman MS, Paietta E, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Rabadan R, Van Vlierberghe P, Ferrando AA. Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. Cancer discovery. 2019 Mar;9(3):436-451. Epub 2018 Dec 19. PMID: 30567843
  • Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, Lazarus HM, Paietta EM, Tallman MS, Litzow MR. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. British journal of haematology. 2021 Jul;194(2):309-318. Epub 2021 Jun 17. PMID: 34145576
  • Smith MR, Hong F, Li H, Gordon LI, Gascoyne RD, Paietta EM, Advani RH, Forero-Torres A, Horning SJ, Kahl BS. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia. 2017 Feb;31(2):517-519. Epub 2016 Oct 26. PMID: 27780968
  • Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American journal of hematology. 2019 Jan;94(1):111-117. Epub 2018 Nov 15. PMID: 30370956
  • Abshiru NA, Sikora JW, Camarillo JM, Morris JA, Compton PD, Lee T, Neelamraju Y, Haddox S, Sheridan C, Carroll M, Cripe LD, Tallman MS, Paietta EM, Melnick AM, Thomas PM, Garrett-Bakelman FE, Kelleher NL. Targeted detection and quantitation of histone modifications from 1,000 cells. PloS one. 2020 Oct 26;15(10):e0240829. doi: 10.1371/journal.pone.0240829. eCollection 2020. PMID: 33104722
  • Marcelletti JF, Sikic BI, Cripe LD, Paietta E. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry. Part B, Clinical cytometry. 2019 Jan;96(1):57-66. Epub 2018 Oct 17. PMID: 30334334